The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial
Abstract
MERTK is an essential component of the signaling network that controls phagocytosis in retinal pigment epithelium (RPE), the loss of which results in photoreceptor degeneration. Previous proof-of-concept studies have demonstrated the efficacy of gene therapy using human MERTK (hMERTK) packaged into adeno-associated virus (AAV2) in treating RCS rats and mice with MERTK deficiency. The purpose of this study was to assess the safety of gene transfer via subretinal administration of rAAV2-VMD2-hMERTK in subjects with MERTK-associated retinitis pigmentosa (RP). After a preclinical phase confirming the safety of the study vector in monkeys, six patients (aged 14 to 54, mean 33.3 years) with MERTK-related RP and baseline visual acuity (VA) ranging from 20/50 to <20/6400 were entered in a phase I open-label, dose-escalation trial. One eye of each patient (the worse-seeing eye in five subjects) received a submacular injection of the viral vector, first at a dose of 150 µl (5.96 × 10(10)vg; 2 patients) and then 450 µl (17.88 × 10(10)vg; 4 patients). Patients were followed daily for 10 days at 30, 60, 90, 180, 270, 365, 540, and 730 days post-injection. Collected data included (1) full ophthalmologic examination including best-corrected VA, intraocular pressure, color fundus photographs, macular spectral domain optical coherence tomography and full-field stimulus threshold test (FST) in both the study and fellow eyes; (2) systemic safety data including CBC, liver and kidney function tes…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Based on the results from small cohort studies, increasing the total dose delivered to the eye but dividing AAV particles across more than one subretinal bleb appears to have little impact on the intraocular and systemic immune response compared to if the viral particles were concentrated within a single bleb (Jacobson et al., 2012; Ghazi et al., 2016; Weleber et al., 2016; Le Meur et al.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Ghazi et al., 2016
Citations
Cites
Hartong, D. T., Berson, E. L., & Dryja, T. P. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69740-7 · Cited by 2,924
The Lens Opacities Classification System III
Chylack, L. T. (1993) · Archives of Ophthalmology · doi:10.1001/archopht.1993.01090060119035 · Cited by 2,913
(1985) · Archives of Ophthalmology · doi:10.1001/archopht.1985.01050120030015 · Cited by 2,540
Progress and problems with the use of viral vectors for gene therapy
Thomas, C. E., Ehrhardt, A., & Kay, M. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1066 · Cited by 2,501
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Gene therapy clinical trials worldwide to 2012 – an update
Ginn, S. L., Alexander, I. E., Edelstein, M. L., Abedi, M. R., & Wixon, J. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2698 · Cited by 1,159
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Self-citationMutation of the receptor tyrosine kinase gene Mertk in the retinal dystrophic RCS rat
D'Cruz, P. M. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.4.645 · Cited by 873
Cited by
Non-syndromic retinitis pigmentosa
Verbakel, S. K., van Huet, R. A. C., Boon, C. J. F., den Hollander, A. I., Collin, R. W. J., Klaver, C. C. W., Hoyng, C. B., Roepman, R., & Klevering, B. J. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.03.005 · Cited by 973
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
Drugging the efferocytosis process: concepts and opportunities
Mehrotra, P., & Ravichandran, K. S. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00470-y · Cited by 459
How macrophages deal with death
Lemke, G. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0167-y · Cited by 433
Metadata
- Authors
- Ghazi, N. G., Abboud, E. B., Nowilaty, S. R., Alkuraya, H., Alhommadi, A., Cai, H., Hou, R., Deng, W.-T., Boye, S. L., Almaghamsi, A., Al Saikhan, F., Al-Dhibi, H., Birch, D., Chung, C., Colak, D., LaVail, M. M., Vollrath, D., Erger, K., Wang, W., Conlon, T., Zhang, K., Hauswirth, W., & Alkuraya, F. S.
- Affiliations
- King Khaled Eye Specialist Hospital (SA)
- Imam Mohammad ibn Saud Islamic University (SA)
- University of California San Diego (US)
- University of Florida (US)
- Retina Foundation of the Southwest (US)
- University of California, San Francisco (US)
- Stanford Medicine (US)
- Alfaisal University (SA)
- Corresponding author
- Alkuraya, Fowzan S.
- ORCID
- Venue
- Human Genetics
- Published
- 2016-01-29
- Volume
- 135
- Issue
- 3
- Pages
- 327-343
- ISSN
- 0018-7348 (ISSN-L)
- 0340-6717
- 1432-1203
- OpenAlex
- W2255190151
- Semantic Scholar
- eff9c1e037daaf88b4893e3006583320d4ca3fc0
- Cited by
- 243
- References
- 43
- Citations by year
- 2026: 11 · 2025: 18 · 2024: 22 · 2023: 10 · 2022: 26 · 2021: 30 · 2020: 22 · 2019: 26 · 2018: 31 · 2017: 32 · 2016: 13
- FWCI
- 17.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Human Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- King Salman Center for Disaiblity Research
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- retinitis pigmentosa, gene therapy, adeno-associated virus vectors, AAV2, subretinal injection, retinal pigment epithelium, phagocytosis, photoreceptor degeneration, vector safety, dose escalation, visual acuity, retinal function, adverse events
- MeSH terms
- c-Mer Tyrosine Kinase, Dependovirus, Adolescent, Adult, Animals, Disease Models, Animal, Female, Follow-Up Studies, Genetic Vectors, Humans, Macaca, Male, Middle Aged, Mutation, Postoperative Complications, Proto-Oncogene Proteins, Retinitis Pigmentosa, Visual Acuity, Genetic Therapy, Treatment Outcome, Receptor Protein-Tyrosine Kinases, Endpoint Determination, Tomography, Optical Coherence, Young Adult, Subretinal Fluid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial. https://app.cochat.ai/papers/10.1007/s00439-016-1637-y
- The paper
- Ghazi, N. G., Abboud, E. B., Nowilaty, S. R., Alkuraya, H., Alhommadi, A., Cai, H., Hou, R., Deng, W.-T., Boye, S. L., Almaghamsi, A., Al Saikhan, F., Al-Dhibi, H., Birch, D., Chung, C., Colak, D., LaVail, M. M., Vollrath, D., Erger, K., Wang, W., . . . Alkuraya, F. S. (2016). Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial. Human Genetics. https://doi.org/10.1007/s00439-016-1637-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.